South Korea's Bridge Biotherapeutics Inc. has enlisted San Francisco-based AI drug discovery shop Atomwise Inc. to help it identify up to 13 small-molecule inhibitors of Pellino proteins and other targets in an effort to develop new therapies for inflammatory diseases. Atomwise stands to receive an up-front payment of undisclosed value, as well as milestone and royalty payments under terms of the deal. Presuming success, it estimates the partnership's payoff could reach up to $1.08 billion.
Vir Biotechnology Inc. and Alnylam Pharmaceuticals Inc. are expanding an infectious disease collaboration begun three years ago to take on the coronavirus. The effort now includes developing and commercializing RNAi therapies targeting SARS-CoV-2, the virus that triggers COVID-19, by developing siRNAs identified by Alnylam.
Abpro Therapeutics Inc. has granted an exclusive license to Abpro Bio Co. Ltd., the former Ugint Co. Ltd., to develop and commercialize two bispecific antibodies in Asian markets, including greater China, Japan and South Korea.
Gilead Sciences Inc. will acquire Forty Seven Inc. for $4.9 billion, or $95.50 per share in cash, bringing Gilead magrolimab, an anti-CD47 monoclonal antibody being developed to treat several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).
SAN DIEGO – At the Biocom 10th Annual Global Life Sciences Partnering Conference, panels of pharma executives highlighted what they're looking for to supplement their pipelines and offered advice that ran the gamut from company formation to the courting process to strategies for partnering pipeline drugs and platforms.
Launching a broad new front in its long-running battle against dementia and other neurological diseases, Biogen Inc. has moved to license multiple Sangamo Therapeutics Inc. programs for $350 million up front plus up to $2.37 billion in development, regulatory and commercial milestone payments.
Aptevo Therapeutics Inc.’s chief scientific officer, Jane Gross, told BioWorld that the sale of the firm’s marketed recombinant hemophilia B therapeutic, Ixinity, to Medexus Pharmaceuticals Inc. allowed for a “cleaner message” to Wall Street. “It was a little difficult to explain having a commercial asset and an R&D pipeline,” she said.
Bicycle Therapeutics plc said Roche Holding AG's Genentech Inc. has agreed to pay $30 million up front for rights to develop and commercialize up to four potential immuno-oncology therapies using the company's bicyclic peptide platform. Bicycle will be responsible for all discovery and lead optimization, while Genentech will take up R&D beyond that.
Paris-based Sanofi SA, responding to increasing medicine shortages and drugmakers' heavy reliance on active pharmaceutical ingredients (APIs) sourced from Asia, said it plans to create a major new API manufacturer headquartered in France.
RSS
